Supplemental material
Hematology
Volume 24, 2019 - Issue 1
Related Research Data
DNA methylation changes in leukaemia
Source:
Elsevier BV
Prognosis of Acute Myeloid Leukemia in the General Population: Data from Southern Switzerland
Source:
SAGE Publications
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis
Source:
Ferrata Storti Foundation (Haematologica)
Genetic and epigenetic alterations of myeloproliferative disorders
Source:
Springer Nature
Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly
Source:
Alphamed Press
Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
Source:
American Association for Cancer Research (AACR)
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
Source:
Informa UK Limited
Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone 1 1Edited by J. Karn
Source:
Elsevier BV
Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Source:
Taylor & Francis
Origins of aberrant DNA methylation in acute myeloid leukemia
Source:
Springer Nature
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Source:
Springer Nature
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity
Source:
American Society of Hematology
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
Source:
American Society of Hematology
Management of Refractory Acute Myeloid Leukemia: Re-induction Therapy or Straight to Transplantation?
Source:
Springer Nature
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML
Source:
Wiley-Blackwell
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
Source:
American Society of Hematology
Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines
Source:
American Association for Cancer Research (AACR)
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
Source:
Wiley-Blackwell
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
Source:
Impact Journals, LLC
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Source:
American Society of Hematology
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
Source:
American Society of Clinical Oncology (ASCO)
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study
Source:
Springer Science and Business Media LLC
Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis
Source:
Taylor & Francis
A phase I study of decitabine and rapamycin in relapsed/refractory AML
Source:
Elsevier BV
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
Source:
Springer Nature
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia
Source:
Elsevier BV
Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
Source:
Wiley-Blackwell
Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia
Source:
Wiley-Blackwell
Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors
Source:
Elsevier BV
Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia
Source:
Elsevier BV
The role of decitabine in the treatment of myelodysplastic syndromes
Source:
Informa Healthcare
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia
Source:
American Society of Hematology
DNA methylation and gene silencing in cancer
Source:
Springer Nature
Current and emerging therapies for acute myeloid leukemia.
Source:
Elsevier BV
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Source:
Massachusetts Medical Society
Decitabine for acute myeloid leukemia
Source:
Informa UK Limited
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
Source:
Impact Journals, LLC
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Source:
Proceedings of the National Academy of Sciences
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
Source:
Ferrata Storti Foundation (Haematologica)
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
Source:
American Society of Hematology
Drug therapy for acute myeloid leukemia.
Source:
American Society of Hematology
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
Source:
American Society of Hematology
Linking provided by
